The National Health Commission (“NHC”) of the People’s Republic of China (“PRC”) released the Guidelines on the Clinical Application of New Anti-tumour Drugs (“Guidelines”) on 21 September 2018. New Anti-tumour drugs refer to small-molecule targeted medicines and large-molecule monoclonal antibody medicines under the Guidelines.
The Guidelines are divided into two parts. The first part introduces some general principles on anti-tumour drugs. For instance, preconditions of the application of the anti-tumour drugs include: the diagnosis of the malignant tumour being confirmed through histopathology and anti-tumour drugs with specific targets must pass the genetic testing. The second part introduces 42 types of anti-tumour drugs and their application principles.
To read the full text of the Guidelines (in Chinese only), please click here.